Douglas A. Scott v. PerkinElmer Health Sciences, Inc.

CourtDistrict Court, N.D. California
DecidedApril 10, 2026
Docket5:24-cv-03389
StatusUnknown

This text of Douglas A. Scott v. PerkinElmer Health Sciences, Inc. (Douglas A. Scott v. PerkinElmer Health Sciences, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Douglas A. Scott v. PerkinElmer Health Sciences, Inc., (N.D. Cal. 2026).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 DOUGLAS A. SCOTT, Case No. 24-cv-03389-SVK

8 Plaintiff, ORDER GRANTING IN PART MOTION TO DISMISS AND 9 v. CONVERTING IN PART MOTION TO DISMISS INTO MOTION FOR 10 PERKINELMER HEALTH SCIENCES, SUMMARY JUDGMENT AND INC., GRANTING SUMMARY JUDGMENT 11 Defendant. Re: Dkt. No. 11 12 13 Defendant moves to dismiss all six of self-represented Plaintiff’s claims. See Dkts. 11 (the 14 “Motion”), 24 (the “Opposition”), 25. Plaintiff and Defendant have consented to the jurisdiction 15 of a magistrate judge, and the Court has determined that the Motion is suitable for resolution 16 without oral argument. See Dkts. 9, 18; Civil Local Rule 7-1(b). For the reasons set forth below, 17 the Court GRANTS IN PART Defendant’s Motion to Dismiss and DISMISSES three of 18 Plaintiff’s claims for lack of standing and CONVERTS IN PART the Motion into one for 19 summary judgment and GRANTS summary judgment to Defendant the three remaining claims.1 20 I. BACKGROUND 21 A. Factual History 22 The following discussion of background facts is based on the allegations contained in the 23 complaint. See Dkt. 1, Ex. A (the “Complaint”). In 2017, Plaintiff operated two “cannabis 24 testing” laboratories in Salinas, California. See id. ¶¶ 10, 12. In 2018, he purchased three 25 “instruments” for the laboratories from Defendant: (1) the QSight 220; (2) the Flexar-HPLC; and 26 27 1 The Court’s prior Order resolving the Motion was VACATED on April 10, 2026, pursuant to the Court’s Order on Plaintiff’s Rule 60(b) motion for relief from final judgment. This Order 1 (3) the NexION-ICP/MS. See id. ¶¶ 11, 86, 97, 110. In purchasing the instruments, Plaintiff 2 relied on representations by Defendant about the instruments’ functionality and capabilities. See 3 id. ¶¶ 65, 86. Plaintiff subsequently encountered issues with the instruments such that they did not 4 conform to Defendant’s representations. See id. ¶¶ 73-75. He then commenced this action in the 5 Superior Court for the County of Monterey on March 11, 2024, to recover from Defendant for its 6 alleged misrepresentations in connection with its sale of the instruments.2 See id. ¶¶ 76-140. 7 Defendant later removed the action to this Court. See Dkt. 1. 8 As Defendant points out and Plaintiff does not dispute, the orders for equipment were 9 placed by Plaintiff on behalf of American Biotech Testing, Inc. (“ABT”), “which Plaintiff owned 10 and ran as CEO.” Dkt. 32 at 5 (Defendant’s opposition); Dkt. 11-2, Exs. A-C (Sales Order 11 Confirmations); Dkt. 31-1, ¶¶ 9-10 (declaring that “American Biotech Testing, Inc. held the 12 contracts at issue, discovered fraud later, and continues to pursue claims in a pending RICO group 13 action in Massachusetts.”). Nonetheless, Plaintiff brought the fraud, implied warranty, and 14 rescission claims in his own name in this case. See Dkt. 1, Ex. A. 15 B. Relevant Procedural History 16 Upon initial review of the briefing, the Court observed that Defendant moved to dismiss all 17 of Plaintiff’s claims for, inter alia, exceeding the scope of the relevant statutes of limitations. See 18 Motion at 19-28. In broaching this argument, Defendant relied on evidence outside the Complaint 19 regarding the dates on which it delivered and installed the instruments and implicitly invited the 20 Court to entertain converting the Motion into one for summary judgment so that the Court could 21 properly consider that extrinsic evidence.3 See id. at 19-20; Dkt. 11-3. The Court consequently 22

23 2 Plaintiff also purchased a fourth instrument, the Torian T9 Portable GC (which he also refers to as “Torion”), from Defendant. See Complaint ¶¶ 11, 86. But he offers relatively few allegations 24 about that specific instrument or issues he encountered with it, and so it does not appear that he bases any of his claims on the purchase of that instrument. See id. ¶¶ 11, 39. Defendant raises this 25 precise issue in the Motion (see Motion at 12 n.3), and Plaintiff does not address it in the 26 Opposition. The Court, therefore, understands Plaintiff’s claims to concern his purchases of only the QSight 220, Flexar-HPLC and NexION-ICP/MS. 27 3 The invitation is implicit in that Defendant cites to Jablon v. Dean Witter & Company, 614 F.2d 1 issued an order in which it: (1) noted that converting the Motion into one for summary judgment 2 “may be appropriate here”; (2) offered Plaintiff an opportunity to present his own evidence about 3 the instruments’ delivery and installation dates; and (3) cautioned Plaintiff that if he did “not file 4 any supplemental submission by the deadline, [then] the Court w[ould] construe that failure to 5 submit as a concession regarding the accuracy of the dates.” See Dkt. 28 at 1-2. Plaintiff never 6 submitted a supplemental filing on the issue. 7 II. DISCUSSION 8 Plaintiff brings six claims in connection with the instruments’ alleged failure to conform 9 with Defendant’s representations: 10 • Three claims for fraud and deceit under Section 1709 of the California Civil Code.4 See 11 Complaint ¶¶ 76-113. 12 • Two claims for breaches of the implied warranties of merchantability and fitness. See id. 13 ¶¶ 114-33. 14 • One claim for rescission and restitution. See id. ¶¶ 134-40. 15 Defendant argues that Plaintiff fails to state any of his claims because all of them are time 16 barred under the applicable statutes of limitations. See Motion at 19-28. Defendant also puts forth 17 a brief argument that Plaintiff lacks standing to bring any of the claims and that such claims must 18 be brought, if at all, by ABT. Dkt. 11 at 17-18. “[A] federal court generally may not rule on the 19 20 affidavits.” See Motion at 20 (citing Dean Witter, 614 F.2d at 682) (quotation marks omitted). 21 Defendant does not expressly discuss converting the Motion into one for summary judgment in the context of analyzing its statute-of-limitations defense, but a close reading of the Dean Witter 22 decision clarifies that the Court could consider Defendant’s evidence in connection with 23 evaluating that defense only by converting the Motion into one for summary judgment. See Dean Witter, 614 F.2d at 682; accord McGee v. Cnty. of Riverside, No. 21-cv-01821-JVS, 2022 WL 24 2168885, at *1 (C.D. Cal. Apr. 20, 2022). 4 In the Complaint, Plaintiff refers to Section 1710 instead of Section 1709 in connection with his 25 fraud-and-deceit claims. Section 1709 prohibits engaging in willful deception, while Section 1710 26 provides four definitions of deceit “within the meaning of” Section 1709. See Cal. Civ. Code §§ 1709-10. Plaintiff cites to three of those definitions in connection with his fraud-and-deceit 27 claims, and so the Court understands Plaintiff to actually be pursuing three claims under Section 1 merits of a case without first determining that it has jurisdiction over the category of claim in suit 2 (subject-matter jurisdiction) and the parties (personal jurisdiction).” Sinochem Int'l Co. v. 3 Malaysia Int'l Shipping Corp., 549 U.S. 422, 430-31 (2007). “[A] dismissal on statute-of- 4 limitations grounds is ‘a judgment on the merits.’” Baiul-Farina v. Lemire, 804 F. App’x 533, 5 538 (9th Cir. 2020) (quoting Plaut v. Spendthrift Farm, Inc., 514 U.S. 211, 228 (1995)). 6 Accordingly, prior to turning to Defendant’s statute-of-limitations defense, the Court evaluates 7 whether Plaintiff has standing to bring, and the Court has jurisdiction to hear, this case. 8 A.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Plaut v. Spendthrift Farm, Inc.
514 U.S. 211 (Supreme Court, 1995)
Allen T. Gabree v. Edward J. King
614 F.2d 1 (First Circuit, 1980)
White v. Lee
227 F.3d 1214 (Ninth Circuit, 2000)
Philip Pulver v. Battelle Memorial Institute
536 F. App'x 730 (Ninth Circuit, 2013)
Norgart v. Upjohn Co.
981 P.2d 79 (California Supreme Court, 1999)
Jolly v. Eli Lilly & Co.
751 P.2d 923 (California Supreme Court, 1988)
Hamilton Materials, Inc. v. Dow Chemical Corp.
494 F.3d 1203 (Ninth Circuit, 2007)
In Re Brocade Communications Systems, Inc. Derivative Litigation
615 F. Supp. 2d 1018 (N.D. California, 2009)
Pulver v. Avco Financial Services
182 Cal. App. 3d 622 (California Court of Appeal, 1986)
Fox v. Ethicon Endo-Surgery, Inc.
110 P.3d 914 (California Supreme Court, 2005)
City of Pomona v. Sqm North America Corporation
750 F.3d 1036 (Ninth Circuit, 2014)
People v. Superior Court
159 Cal. App. 4th 1 (California Court of Appeal, 2007)
Rogan O' Handley v. Shirley Weber
62 F.4th 1145 (Ninth Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
Douglas A. Scott v. PerkinElmer Health Sciences, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/douglas-a-scott-v-perkinelmer-health-sciences-inc-cand-2026.